DE69110219D1 - 3-(1H-Indazol-3-yl)-4-pyridiname, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung als Arzneimittel. - Google Patents

3-(1H-Indazol-3-yl)-4-pyridiname, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung als Arzneimittel.

Info

Publication number
DE69110219D1
DE69110219D1 DE69110219T DE69110219T DE69110219D1 DE 69110219 D1 DE69110219 D1 DE 69110219D1 DE 69110219 T DE69110219 T DE 69110219T DE 69110219 T DE69110219 T DE 69110219T DE 69110219 D1 DE69110219 D1 DE 69110219D1
Authority
DE
Germany
Prior art keywords
hydrogen
loweralkyl
indazol
intermediates
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69110219T
Other languages
English (en)
Other versions
DE69110219T2 (de
Inventor
Richard Charles Effland
Joseph Thomas Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Hoechst Roussel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharmaceuticals Inc filed Critical Hoechst Roussel Pharmaceuticals Inc
Publication of DE69110219D1 publication Critical patent/DE69110219D1/de
Application granted granted Critical
Publication of DE69110219T2 publication Critical patent/DE69110219T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
DE69110219T 1990-09-10 1991-09-10 3-(1H-Indazol-3-yl)-4-pyridiname, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung als Arzneimittel. Expired - Fee Related DE69110219T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/579,751 US5051430A (en) 1990-09-10 1990-09-10 3-(1H-indazol-3-yl)-4-pyridinamines

Publications (2)

Publication Number Publication Date
DE69110219D1 true DE69110219D1 (de) 1995-07-13
DE69110219T2 DE69110219T2 (de) 1995-11-09

Family

ID=24318208

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69110219T Expired - Fee Related DE69110219T2 (de) 1990-09-10 1991-09-10 3-(1H-Indazol-3-yl)-4-pyridiname, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung als Arzneimittel.

Country Status (20)

Country Link
US (1) US5051430A (de)
EP (1) EP0475352B1 (de)
JP (1) JP3042915B2 (de)
KR (1) KR100203236B1 (de)
AT (1) ATE123493T1 (de)
AU (1) AU640590B2 (de)
CA (1) CA2050875C (de)
CZ (1) CZ280883B6 (de)
DE (1) DE69110219T2 (de)
DK (1) DK0475352T3 (de)
ES (1) ES2074618T3 (de)
FI (1) FI914219A (de)
HU (1) HUT59126A (de)
IE (1) IE67442B1 (de)
IL (1) IL99434A (de)
NO (1) NO913543L (de)
NZ (1) NZ239692A (de)
PL (1) PL295728A1 (de)
PT (1) PT98911B (de)
ZA (1) ZA917141B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ282665B6 (cs) * 1989-12-27 1997-08-13 Hoechst Marion Roussel, Inc. Aminopyridinylmethanoly, aminomethylpyridinaminy a jejich deriváty, způsob jejich přípravy, farmaceutický prostředek obsahující tyto sloučeniny a použití
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
ATE449763T1 (de) * 2001-04-16 2009-12-15 Eisai R&D Man Co Ltd 1h-indazolverbindungen die jnk hemmen
WO2005085227A1 (en) * 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibitors of akt activity
EP1871766A4 (de) * 2005-03-30 2010-07-21 Dae Woong Pharma Triazolderivate mit antipilzwirkung

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU198036B (en) * 1983-08-22 1989-07-28 Hoechst Roussel Pharma Process for production of derivatives of 3-piperidil-/1h/-indasole and medical preparatives containing them

Also Published As

Publication number Publication date
KR920006346A (ko) 1992-04-27
HU912901D0 (en) 1992-01-28
FI914219A (fi) 1992-03-11
HUT59126A (en) 1992-04-28
CZ280883B6 (cs) 1996-04-17
NO913543L (no) 1992-03-11
IL99434A (en) 1995-08-31
NZ239692A (en) 1994-01-26
CS277691A3 (en) 1992-04-15
PL295728A1 (en) 1993-05-04
IE67442B1 (en) 1996-04-03
FI914219A0 (fi) 1991-09-06
US5051430A (en) 1991-09-24
ATE123493T1 (de) 1995-06-15
NO913543D0 (no) 1991-09-09
KR100203236B1 (ko) 1999-06-15
IE913157A1 (en) 1992-03-11
EP0475352A1 (de) 1992-03-18
CA2050875A1 (en) 1992-03-11
JPH04247079A (ja) 1992-09-03
JP3042915B2 (ja) 2000-05-22
CA2050875C (en) 2002-07-16
DK0475352T3 (da) 1995-10-16
AU640590B2 (en) 1993-08-26
DE69110219T2 (de) 1995-11-09
EP0475352B1 (de) 1995-06-07
PT98911A (pt) 1992-07-31
IL99434A0 (en) 1992-08-18
ZA917141B (en) 1992-04-29
ES2074618T3 (es) 1995-09-16
PT98911B (pt) 1999-02-26
AU8371691A (en) 1992-03-12

Similar Documents

Publication Publication Date Title
ATE163012T1 (de) N-substituierte 4-pyrimidinamine und - pyrimidindiamine, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel
DE69418789T2 (de) 2-(Piperidin-4-yl, Pyridin-4-yl und Tetrahydropyridin-4-yl)-benzofuran-7-carbamat Derivate, ihre Herstellung und Verwendung als Acetylcholinesterase Inhibitoren
DE69022294T2 (de) N-Heteroaryl-purin-6-amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
DE69028605T2 (de) Aminocarbonylcarbamate verwandt mit Physostigmin, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE69110219D1 (de) 3-(1H-Indazol-3-yl)-4-pyridiname, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
DE69402935T2 (de) Substituierte arylalkylaminobenzyl-aminopropanamide, ihre herstellung und verwendung als antiepileptische, neuroprotektive und antidepressive mittel
ATE130004T1 (de) 3-(1,2-benzisoxazol-3-yl)-4-pyridinamine und derivate.
DE68914600T2 (de) Kondensierte heterocyclische Derivate von 1,2,3,4-Tetrahydroacridin, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament.
DE69209242D1 (de) 2-(3-Phenylpropyl)hydrazine, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung als Medikamente

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee